NCT05946486View on ClinicalTrials.gov

Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

174

Participants

Timeline

Start Date

October 15, 2023

Primary Completion Date

January 15, 2026

Study Completion Date

December 15, 2026

Conditions

Mental Disorder

Interventions

DRUG

immunomodulatory treatment by rituximab

1g for adults or 375 mg/m2 for children, renewed at 14 days (+/- 3 days)

Trial Locations (9)

Unknown

Centre Hospitalier Charles Perrens, Bordeaux

CHU de Bordeaux, Bordeaux

Centre hospitalier le Vinatier, Bron

CHU de Clermond Ferrand, Clermont-Ferrand

APHP Louis Mourier, Colombes

APHP Henri Mondor, Créteil

APHP Kremlin Bicetre, Le Kremlin-Bicêtre

CHU de Montpellier, Montpellier

CHU de Strasbourg, Strasbourg

All Listed Sponsors

lead

University Hospital, Bordeaux

OTHER

NCT05946486 - Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity. | Biotech Hunter | Biotech Hunter